Evidence map›Paper›PMID 34320970›Full record

ArticleBMC medical ethics2021

Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices.

Raffaella Ravinetto, Céline Caillet, Muhammad H Zaman, Jerome Amir Singh, Philippe J Guerin, Aasim Ahmad, Carlos E Durán, Amar Jesani, Ana Palmero, Laura Merson and 4 more

Abstract read
In one paragraph

Article in BMC medical ethics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Peer Review inJAACAP open · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Raffaella RavinettoInstitute of Tropical Medicine, Nationalestraat 155, 2000, Antwerp, Belgium. rravinetto@itg.be.ORCID 0000-0001-7765-2443
Céline CailletInfectious Diseases Data Observatory (IDDO), University of Oxford, Oxford, UK.
Muhammad H ZamanBoston University, Boston, MA, USA.
Jerome Amir SinghHoward College School of Law, University of Kwazulu-Natal, Durban, South Africa.
Philippe J GuerinInfectious Diseases Data Observatory (IDDO), University of Oxford, Oxford, UK.
Aasim AhmadBioethics Group, Aga Khan University, Karachi, Pakistan.
Carlos E DuránJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Amar JesaniIndian Journal of Medical Ethics, Mumbai, India.
Ana PalmeroCenter for the Study of the State and Society, Buenos Aires, Argentina.
Laura MersonInfectious Diseases Data Observatory (IDDO), University of Oxford, Oxford, UK.
Peter W HorbyCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
E BottieauInstitute of Tropical Medicine, Nationalestraat 155, 2000, Antwerp, Belgium.
Tammy HoffmannInstitute for Evidence-Based Healthcare, Bond University, Gold Coast, Australia.
Paul N NewtonInfectious Diseases Data Observatory (IDDO), University of Oxford, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over recent years, the research community has been increasingly using preprint servers to share manuscripts that are not yet peer-reviewed. Even if it enables quick dissemination of research findings, this practice raises several challenges in publication ethics and integrity. In particular, preprints have become an important source of information for stakeholders interested in COVID19 research developments, including traditional media, social media, and policy makers. Despite caveats about their nature, many users can still confuse pre-prints with peer-reviewed manuscripts. If unconfirmed but already widely shared first-draft results later prove wrong or misinterpreted, it can be very difficult to "unlearn" what we thought was true. Complexity further increases if unconfirmed findings have been used to inform guidelines. To help achieve a balance between early access to research findings and its negative consequences, we formulated five recommendations: (a) consensus should be sought on a term clearer than 'pre-print', such as 'Unrefereed manuscript', "Manuscript awaiting peer review" or ''Non-reviewed manuscript"; (b) Caveats about unrefereed manuscripts should be prominent on their first page, and each page should include a red watermark stating 'Caution-Not Peer Reviewed'; (c) pre-print authors should certify that their manuscript will be submitted to a peer-review journal, and should regularly update the manuscript status; (d) high level consultations should be convened, to formulate clear principles and policies for the publication and dissemination of non-peer reviewed research results; (e) in the longer term, an international initiative to certify servers that comply with good practices could be envisaged.

Indexed as

COVID-19Social MediaHumansPeer Review, ResearchPreprints as TopicSARS-CoV-2

Identifiers

PMID34320970
PMCPMC8320096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.